Targeted Microdosing for Precision Drug Development 

The MicroTex Hub is pioneering the invention and development of new technologies to transform Phase-0 Intra-Target Microdosing (ITM) into a viable, effective method of accelerating drug discovery. ITM involves delivering minute quantities of a drug to a precisely targeted microscale region of the body, so researchers can assess early signs of efficacy without systemic exposure. To make this possible, we are creating high-precision robotic delivery systems that enable reproducible, localised administration of microdoses, MicroTex is initially focusing on the lung and cornea.

Next Generation Measurement and Imaging Tools 

To measure the effects of microdosing directly at the site of delivery, MicroTex is advancing a range of cutting-edge sensing and imaging technologies to provide real-time, high-resolution insight into therapeutic responses. By detecting biological signals of inflammation, infection, or metabolic activity, these tools will help researchers make earlier, more informed decisions about the likely success of early-stage drug candidates.

Miniaturised Sensors and Technologies 

The Hub will also deliver a new generation of miniaturised electrochemical and optical sensors. These sensors will be able to detect a wide range of biomarkers—such as pH, enzyme activity, oxygen levels, and microbial presence—with high sensitivity and specificity. Platforms like smart contact lenses and microneedle patches may be used to deliver drugs and monitor responses, opening new opportunities for less invasive, patient-friendly diagnostics and treatments.

Microfabrication, Integration, and Computational Imaging 

Supporting these developments is a suite of microfabrication and micromechanical platforms for building and refining bespoke microscale tools. These technologies will enable customisation and scalability of the ITM toolkit. Complementing the hardware will be advanced computational imaging and data integration systems designed to interpret the rich datasets produced during trials—ensuring robust analysis and streamlined decision-making in the drug development process.